Drug Database
ET

ethinyl estradiol (Oestrogel)

✓ Approved

Sanofi S.A · ESR1 · 小分子

什么是 ethinyl estradiol?

ethinyl estradiol 是一种小分子,由Sanofi S.A研发。该药已获批,用于治疗相关适应症,给药途径:Transdermal。

药物档案

商品名Oestrogel
公司Sanofi S.A
药物类别小分子
分子靶点ESR1
给药途径Transdermal
状态Approved

作用机制

分子靶点

ethinyl estradiol 作用于 1 个分子靶点:

ESR1estrogen receptor 1 (ER, ESR)
需要更深入的分析?Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

ethinyl estradiol 针对 1 个适应症,涉及 1 个治疗领域。

治疗领域疾病/病症分期
Surgical and medical proceduresHormone replacement therapy✓ Approved

相关研究文献

PubMedBiomeditsinskaia khimiia2026-11-18

The effect of the synthetic analogue of kisspeptin on the level of hormones of the reproductive system in Danio rerio.

Kostina M I MI, Blazhenko A A AA, Glebskaya S A SA, Nuzhnova A A AA et al.

One of the modern approaches in pharmacology is to conduct research on the Danio rerio model organism, characterized by high genetic conservativeness. Kisspeptin is one of the neuropeptides responsible for regulating reproductive function, and its synthetic analogues may have improved stability and bioavailability. The aim of the research was to study and analyze the effects of the synthetic analogue of kiss1 (SAK1) of D. rerio, consisting of 14 amino acids, produced in the Department of General Pathology and Pathological Physiology of the Institute of Experimental Medicine on female D. rerio fish after spawning. For the experiments, SAK1 and buserelin-depot were used as a reference compound. The fishes were anesthetized using lidocaine, then pharmacological agents were administered intracerebrally into ventricle region (midbrain-cerebellum region). SAK1 was administered at two doses: 1 ng and 4 ng per fish (equivalent to 0.60 pmol and 2.36 pmol). Gonadectomy was performed following the administration of the substance. SAK1 administration caused an increase in the levels of follicle-stimulating hormone (FSH), luteinizing hormone (LH), and progesterone and a decrease in the testosterone levels, without any effect on the estradiol levels. Administration of buserelin increased concentrations of progesterone, FSH, and LH, and decreased testosterone levels without changes in estradiol levels, compared to the control group. The diverse trends observed in hormone level fluctuations (both within and outside the particular biochemical pathway) demonstrate that the peptide exerts both inhibitory and stimulatory effects. This may have significant implications for future research into the regulation of the relevant biological processes.

PMID 43046915
阅读全文 →
PubMedOrthopaedic journal of sports medicine2026-11-18

The Association of Hormone Replacement Therapy With Rotator Cuff Tendinopathy and Rotator Cuff Repair Among Menopausal Women.

Chaljub Claire R CR, Haver Katherine C KC, Pescatore Sabrina M SM, Somerson Jeremy S JS

Rotator cuff (RC) tendinopathy is a common condition that causes shoulder pain and weakness. The decline of estrogen during menopause may increase RC tendinopathy risk. While hormone replacement therapy (HRT) may counteract these effects, its role in tendon health remains unclear. To examine the prevalence of RC tendinopathy and subsequent rotator cuff repair (RCR) surgery among menopausal women taking HRT compared with those not taking HRT. Cohort study; Level of study, 3. The authors utilized the TriNetX database to evaluate RC tendinopathy and subsequent RCR in menopausal women aged 45 to 60 years. Two cohorts were created: (1) menopausal women taking estradiol and (2) menopausal women not taking estradiol. Cohorts were 1 to 1 propensity score matched for hyperlipidemia, osteoarthritis, nicotine dependence, type 2 diabetes, thyrotoxicosis, alcohol-related disorders, rheumatoid arthritis, lupus, injections, body mass index, and demographic factors. Outcomes evaluated were RC tendinopathy diagnosis (International Classification of Diseases, 10th Revision [ICD-10] codes: M67.81, M75.10, M75.11, M75.12, S43.42, M75.4, M75.5) and RCR (Current Procedural Terminology [CPT]: 29827, 23410, 23412, 23420) at 1, 5, and 10 years after HRT. Each cohort included 177,198 menopausal women. Women on HRT had significantly higher rates of RC tendinopathy at 1 year compared with women not taking HRT (odds ratio [OR], 1.095 [95% CI, 1.016-1.179]; P = .018). Significantly more women taking HRT also underwent RCR after 1 year (OR = 1.309 [95% CI, 1.045-1.641]; P = .019). After 5 years on HRT, menopausal women were significantly more likely to be both diagnosed with RC tendinopathy (OR = 1.139 [95% CI, 1.088-1.192]; P < .0001) and undergo RCR (OR = 1.278 [95% CI, 1.122-1.456]; P < .0001). After 10 years on HRT, menopausal women demonstrated a similar trend with increased instances of RC tendinopathy (OR = 1.152 [95% CI, 1.105-1.202]; P < .0001) and RCR (OR = 1.279 [95% CI, 1.137-1.439]; P < .0001). Menopausal women taking HRT had significantly higher instances of RC tendinopathy and RCR at all time points. These findings suggest a potential association between HRT and tendon pathology, warranting further research into the interplay between menopause, HRT, and musculoskeletal health to better inform clinical practice.

PMID 43047897
阅读全文 →
PubMedPhysiological genomics2026-11-18

Editorial Focus on PG-00296-2025R2.

Silva Juneo Freitas JF

Parturition involves coordinated endocrine, inflammatory, extracellular matrix, and mechanical processes that are regulated differently across reproductive tissues. Here, we discuss the study by Davila Ruiz et al., which investigated tissue-specific responses to prepartum estradiol (E2) exposure in pregnant ewes using transcriptomic and protein analyses. The cervix exhibited the most pronounced transcriptional response, particularly in pathways associated with extracellular matrix organization, steroid metabolism, prostaglandin synthesis, and immune signaling, whereas the myometrium and placental membranes showed comparatively limited changes. Reduced myometrial progesterone receptor expression further supports the role of functional progesterone withdrawal in preparing for labor. These findings highlight the cervix as an active molecular target of endocrine signaling rather than merely a passive structural component. Future studies integrating single-cell and spatial transcriptomics should clarify the cellular mechanisms underlying cervical remodeling and determine whether these pathways are conserved in humans, with potential implications for understanding preterm birth and cervical insufficiency.

PMID 43046780
阅读全文 →
PubMedSAGE open medical case reports2026-11-18

The clinical utility of FES-PET with multiple malignancies: A case report of advanced melanoma and breast cancer.

McLaughlin Shannon S, Medford Arielle J AJ, Kim Janice J, Spring Laura L et al.

Differentiating the primary etiology of metastatic lesions in patients with multiple malignancies can create challenges when it is not feasible to perform a biopsy. We present a case of a 62-year-old patient with metastatic estrogen receptor (ER)+/progesterone receptor (PR)+/human epidermal growth factor 2 amplified breast cancer, metastatic melanoma, and chronic lymphocytic leukemia who developed new pulmonary nodules not amenable to biopsy. Classic fluorodeoxyglucose positron emission tomography (PET) computed tomography (CT) imaging revealed metabolically active pulmonary lesions, but was unable to distinguish which primary cancer was responsible for the metastatic lesion. Subsequent PET/CT using 16α-[18F]-fluoro-17β-estradiol ([18F]FES) radioactive tracer, which binds to estrogen receptors, revealed tracer uptake within the pulmonary nodules, supporting that the new nodules were of breast primary, rather than melanoma. This non-invasive imaging was able to provide diagnostic clarity and directly inform management, leading to a change in systemic therapy. This case highlights the value of FES-PET/CT in characterizing ER-positive disease and distinguishing between competing malignancies when tissue biopsy is not feasible.

PMID 43048512
阅读全文 →
PubMedJCEM case reports2026-11-18

Functioning gonadotropinomas with ovarian hyperstimulation and multicystic ovaries: a tale of 2 tumors and 2 organs.

Ghosh Jayaditya J, Mahadevan Shriraam S, Shah Ravi R, Sundaram Sandhya S et al.

Functioning gonadotropinomas are rare pituitary adenomas that secrete biologically active gonadotropins and may present with ovarian hyperstimulation and multicystic ovarian enlargement in premenopausal women, often mimicking primary ovarian disease and leading to delayed diagnosis. We describe 2 women with ovarian manifestations secondary to functioning gonadotropinomas. Case 1 was a 36-year-old woman who presented with a 12-year history of abnormal uterine bleeding and bilateral multicystic ovaries initially suspected to be ovarian neoplasms. Later, she developed progressive visual impairment in the right eye. Laboratory tests showed an elevated follicle-stimulating hormone (FSH) level, and pituitary magnetic resonance imaging revealed a macroadenoma. Transsphenoidal surgery confirmed an FSH/luteinizing hormone-positive gonadotroph adenoma, with postoperative regression of ovarian cysts. Case 2 was a 28-year-old woman who presented with severe abdominal pain and bilateral multicystic ovaries complicated by ovarian torsion requiring unilateral ovariectomy and salpingectomy. Persistent ovarian enlargement with elevated gonadotropins and estradiol prompted endocrine evaluation, revealing a pituitary macroadenoma. Histopathology demonstrated FSH and steroidogenic factor 1-positive functioning gonadotropinoma. Following surgery, ovarian cysts regressed, menstrual cycles normalized within 6 months, and spontaneous conception occurred. These cases emphasize the need to consider pituitary pathology in women with unexplained multicystic ovaries and ovarian hyperstimulation syndrome-like features.

PMID 43047272
阅读全文 →
PubMedJCEM case reports2026-11-18

Differences of sex development associated with asymmetric overgrowth in a patient with 69,XXY/46,XX mosaicism.

Vaiani Elisa E, Caino Silvia S, Marino Roxana R, Daroqui Manuel M et al.

Individuals with both differences in sex development (DSD) and asymmetric overgrowth are rare. This clinical presentation may be associated with chromosomal mosaicism. Multiple methodologies may be needed to establish the diagnosis. An 11-month-old patient was referred for evaluation of DSD and segmental overgrowth. Clinical examination showed right-sided facial enlargement, predominantly left-sided limb overgrowth, macrodactyly, and hypo- and hyperpigmented skin lesions. Genital examination revealed clitoromegaly, a midline urogenital sinus, and a palpable right gonad. Pelvic ultrasonography demonstrated a left-sided hemiuterus and a left intra-abdominal gonad. Gonadal biopsy revealed a dysgenetic testis on the right and an ovary on the left. Serum estradiol was 27 pg/mL (International System of Units [SI], 99.1 pmol/L) (reference range, 7-28 pg/mL [SI, 25.7-102.7 pmol/L]), consistent with female reference values. Post-human chorionic gonadotropin testosterone was 6.3 ng/mL (SI, 21.8 nmol/L) (reference value, >1 ng/mL [SI >3.4 nmol/L]), indicating functional testicular tissue. Peripheral blood karyotype was 46,XX, whereas a fibroblast culture obtained from skin biopsy demonstrated 69,XXY[6]/46,XX[34] mixoploidy. The SRY gene was absent in peripheral blood lymphocytes but was detected in the dysgenetic testis and skin fibroblasts. This case underscores the importance of tissue-directed cytogenetic analysis in individuals with DSD and asymmetric overgrowth when peripheral blood karyotype is normal.

PMID 43047953
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多ethinyl estradiol